Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 7 of 7 results for romiplostim

  1. Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)

    Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.

    Technology appraisal guidance
    Published
    15 December 2022
    View recommendations

    Sections for TA853

  2. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)

    Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA835

  3. Eltrombopag for treating chronic immune thrombocytopenia (TA293)

    Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune thrombocytopenia in adults.

    Technology appraisal guidance
    Last updated
    26 October 2018
    View recommendations

    Sections for TA293

  4. Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)

    Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.

    Technology appraisal guidance
    Last updated
    26 October 2018
    View recommendations

    Sections for TA221

  5. Research recommendations

    data on the long-term outcomes of patients treated with eltrombopag and romiplostim. TA293/2

  6. NICE recommends research generating and analysing observational data including, but not limited to, the existing UK ITP Registry, which collects data on the long-term outcomes of patients treated with eltrombopag and romiplostim.

    data on the long-term outcomes of patients treated with eltrombopag and romiplostim. Any explanatory notes(if applicable) None. Source...

    Research recommendation
    Published
    9 June 2015

  7. Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

    Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    21 October 2014